Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The treatment of giant cell arteritis Fraser JA; Weyand CM; Newman NJ; Biousse VRev Neurol Dis 2008[Sum]; 5 (3): 140-52Although giant cell arteritis (GCA) is a well-known vasculitis sensitive to corticosteroid-mediated immunosuppression, numerous issues of long-term therapeutic management remain unresolved. Because GCA encompasses a broad spectrum of clinical subtypes, ranging from devastating visual loss and neurological deficits to isolated systemic symptoms, the treatment of GCA must be adjusted to each case, and recommendations vary widely in the literature. This article systematically reviews the treatment options for patients with neuro-ophthalmic and neurological complications of GCA, as well as the evidence for possible adjuvant therapies for patients with GCA. Although there is no randomized controlled clinical trial specifically evaluating GCA patients with ocular and neurological complications, we recommend that GCA patients with acute visual loss or brain ischemia be admitted to the hospital for high-dose intravenous methyl-prednisolone, close monitoring, and prevention of steroid-induced complications. Aspirin may also be helpful in these cases. The evidence supporting the use of steroid-sparing immunomodulatory agents such as methotrexate for long-term management remains debated.|Adrenal Cortex Hormones/*therapeutic use[MESH]|Anti-Inflammatory Agents/therapeutic use[MESH]|Brain Ischemia/complications/*therapy[MESH]|Drug Administration Schedule[MESH]|Fibrinolytic Agents/*therapeutic use[MESH]|Giant Cell Arteritis/classification/complications/*therapy[MESH]|Hospitalization[MESH]|Humans[MESH]|Immunosuppressive Agents/*therapeutic use[MESH]|Methotrexate/therapeutic use[MESH]|Methylprednisolone/therapeutic use[MESH]|Optic Neuropathy, Ischemic/complications/*therapy[MESH] |